CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Net Income (Loss) Attributable to Redeemable Noncontrolling Interest
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Net Income (Loss) Attributable to Redeemable Noncontrolling Interest of -$3.49 million for the 12-month period ending 2023-12-30, per its 10-K filed 2024-02-14.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest · last filed 2024-02-14
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-12-30 was -$5.74M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-09-30 was $71.00K, a 85.08% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-07-01 was $1.86M, a 120.28% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-04-01 was $322.00K, a 80.41% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for fiscal 2023 was -$3.49M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for fiscal 2022 was -$4.02M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for fiscal 2021 was -$5.38M, a 730.87% decline from fiscal 2020.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) attributable to redeemable noncontrolling interest for fiscal 2020 was $852.00K.
| Period end | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 12 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-30 | -$5.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$5.67M derived: sum of 2 quarters · filed 2024-02-14 | -$3.81M derived: sum of 3 quarters · filed 2024-02-14 | -$3.49M 10-K · filed 2024-02-14 | |
| 2023-09-30 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.93M derived: sum of 2 quarters · filed 2023-11-08 | $2.25M 10-Q · filed 2023-11-08 | -$4.73M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2023-07-01 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.18M 10-Q · filed 2023-08-09 | -$4.80M derived: sum of 3 quarters · filed 2024-02-14 | -$4.33M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2023-04-01 | $322.00K 10-Q · filed 2023-05-11 | -$6.66M derived: sum of 2 quarters · filed 2024-02-14 | -$6.18M derived: sum of 3 quarters · filed 2024-02-14 | -$5.34M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-12-31 | -$6.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$6.51M derived: sum of 2 quarters · filed 2024-02-14 | -$5.66M derived: sum of 3 quarters · filed 2024-02-14 | -$4.02M 10-K · filed 2024-02-14 | |
| 2022-09-24 | $476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.32M derived: sum of 2 quarters · filed 2023-11-08 | $2.96M 10-Q · filed 2023-11-08 | -$6.09M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-06-25 | $843.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.49M 10-Q · filed 2023-08-09 | -$6.56M derived: sum of 3 quarters · filed 2024-02-14 | -$5.49M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-03-26 | $1.64M 10-Q · filed 2023-05-11 | -$7.41M derived: sum of 2 quarters · filed 2024-02-14 | -$6.33M derived: sum of 3 quarters · filed 2024-02-14 | -$5.45M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2021-12-25 | -$9.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$7.97M derived: sum of 2 quarters · filed 2024-02-14 | -$7.09M derived: sum of 3 quarters · filed 2024-02-14 | -$5.38M 10-K · filed 2024-02-14 | |
| 2021-09-25 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $1.96M derived: sum of 2 quarters · filed 2022-11-02 | $3.67M 10-Q · filed 2022-11-02 | $5.80M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-26 | $883.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $2.60M 10-Q · filed 2022-08-03 | $4.73M derived: sum of 3 quarters · filed 2023-02-22 | $3.99M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-27 | $1.72M 10-Q · filed 2022-05-04 | $3.85M derived: sum of 2 quarters · filed 2023-02-22 | $3.11M derived: sum of 3 quarters · filed 2023-02-22 | $2.90M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-26 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.39M derived: sum of 2 quarters · filed 2023-02-22 | $1.18M derived: sum of 3 quarters · filed 2023-02-22 | $852.00K 10-K · filed 2023-02-22 | -$852.00K 10-K · filed 2021-02-17 |
| 2020-09-26 | -$740.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$946.00K derived: sum of 2 quarters · filed 2021-11-03 | -$1.28M 10-Q · filed 2021-11-03 | -$1.57M derived: sum of 4 quarters · filed 2021-11-03 | |
| 2020-06-27 | -$206.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$538.00K 10-Q · filed 2021-08-04 | -$829.00K derived: sum of 3 quarters · filed 2021-08-04 | -$864.00K derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-28 | -$332.00K 10-Q · filed 2021-05-04 | -$623.00K derived: sum of 2 quarters · filed 2021-05-04 | -$658.00K derived: sum of 3 quarters · filed 2021-05-04 | -$459.00K derived: sum of 4 quarters · filed 2021-05-04 | |
| 2019-12-28 | -$291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$326.00K derived: sum of 2 quarters · filed 2021-02-17 | -$127.00K derived: sum of 3 quarters · filed 2021-02-17 | -$42.00K 10-K · filed 2021-02-17 | |
| 2019-09-28 | -$35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $164.00K derived: sum of 2 quarters · filed 2020-10-29 | $249.00K 10-Q · filed 2020-10-29 | $506.00K derived: sum of 4 quarters · filed 2020-10-29 | |
| 2019-06-29 | $199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $284.00K 10-Q · filed 2020-08-05 | $541.00K derived: sum of 3 quarters · filed 2020-08-05 | $707.00K derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-30 | $85.00K 10-Q · filed 2020-05-07 | $342.00K derived: sum of 2 quarters · filed 2020-05-07 | $508.00K derived: sum of 3 quarters · filed 2020-05-07 | ||
| 2018-12-29 | $257.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | $423.00K derived: sum of 2 quarters · filed 2020-02-11 | $800.00K 10-K · filed 2020-02-11 | ||
| 2018-09-29 | $166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $543.00K 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $377.00K 10-Q · filed 2019-07-31 | ||||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 | ||||
| 2016-09-24 | $1.50M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |